Connection

MALCOLM BRENNER to Genetic Vectors

This is a "connection" page, showing publications MALCOLM BRENNER has written about Genetic Vectors.
Connection Strength

4.325
  1. Seek and You Will Not Find: Ending the Hunt for Replication-Competent Retroviruses during Human Gene Therapy. Mol Ther. 2018 01 03; 26(1):1-2.
    View in: PubMed
    Score: 0.445
  2. Mesenchymal Stromal Cells for Linked Delivery of Oncolytic and Apoptotic Adenoviruses to Non-small-cell Lung Cancers. Mol Ther. 2015 Sep; 23(9):1497-506.
    View in: PubMed
    Score: 0.374
  3. Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?". Hum Gene Ther. 2009 Nov; 20(11):1229-39.
    View in: PubMed
    Score: 0.253
  4. Overview of gene therapy clinical progress including cancer treatment with gene-modified T cells. Hematology Am Soc Hematol Educ Program. 2009; 675-81.
    View in: PubMed
    Score: 0.239
  5. Targeted delivery of adenoviral vectors by cytotoxic T cells. Blood. 2004 Oct 15; 104(8):2272-80.
    View in: PubMed
    Score: 0.174
  6. Is retroviral gene marking too dangerous to use? Cytotherapy. 2003; 5(3):190-3.
    View in: PubMed
    Score: 0.158
  7. Response to "systemic adenovirus delivery". Mol Ther. 2002 Aug; 6(2):138.
    View in: PubMed
    Score: 0.153
  8. Bilamellar cationic liposomes protect adenovectors from preexisting humoral immune responses. Mol Ther. 2002 Mar; 5(3):233-41.
    View in: PubMed
    Score: 0.149
  9. Gene-marking studies of hematopoietic cells. Int J Hematol. 2001 Jan; 73(1):14-22.
    View in: PubMed
    Score: 0.137
  10. Reports of adenovector "death" are greatly exaggerated. Mol Ther. 2000 Mar; 1(3):205.
    View in: PubMed
    Score: 0.130
  11. Gene transfer by adenovectors. Blood. 1999 Dec 15; 94(12):3965-7.
    View in: PubMed
    Score: 0.128
  12. IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood. 1998 Sep 15; 92(6):1941-9.
    View in: PubMed
    Score: 0.117
  13. Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies. Cancer Immunol Res. 2018 01; 6(1):47-58.
    View in: PubMed
    Score: 0.110
  14. A novel herpes vector for the high-efficiency transduction of normal and malignant human hematopoietic cells. Blood. 1997 Jan 01; 89(1):119-27.
    View in: PubMed
    Score: 0.104
  15. An Inducible Caspase-9 Suicide Gene to Improve the Safety of Therapy Using Human Induced Pluripotent Stem Cells. Mol Ther. 2015 Sep; 23(9):1475-85.
    View in: PubMed
    Score: 0.093
  16. Immunomodulatory effects of human neuroblastoma cells transduced with a retroviral vector encoding interleukin-2. Cancer Gene Ther. 1994 Dec; 1(4):253-8.
    View in: PubMed
    Score: 0.090
  17. Genetic marking and manipulation of hematopoietic progenitor cells using retroviral vectors. Immunomethods. 1994 Dec; 5(3):204-10.
    View in: PubMed
    Score: 0.090
  18. The eyes have it. Mol Ther. 2010 Mar; 18(3):451-2.
    View in: PubMed
    Score: 0.065
  19. Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood. 2009 Nov 26; 114(23):4784-91.
    View in: PubMed
    Score: 0.063
  20. Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy. J Immunother. 2008 Sep; 31(7):665-74.
    View in: PubMed
    Score: 0.058
  21. Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant. 2007 Aug; 13(8):913-24.
    View in: PubMed
    Score: 0.054
  22. Comparison of the efficiency of transduction of leukemic cells by fiber-modified adenoviruses. Hum Gene Ther. 2004 Dec; 15(12):1229-42.
    View in: PubMed
    Score: 0.045
  23. Genetic modification of T lymphocytes for adoptive immunotherapy. Mol Ther. 2004 Jul; 10(1):5-18.
    View in: PubMed
    Score: 0.044
  24. Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained from 60 clinical trials. Mol Ther. 2023 03 01; 31(3):801-809.
    View in: PubMed
    Score: 0.039
  25. Adenovector-induced expression of human-CD40-ligand (hCD40L) by multiple myeloma cells. A model for immunotherapy. Exp Hematol. 2001 Aug; 29(8):952-61.
    View in: PubMed
    Score: 0.036
  26. Efficient infection of primitive hematopoietic stem cells by modified adenovirus. Gene Ther. 2001 Jun; 8(12):930-7.
    View in: PubMed
    Score: 0.035
  27. Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas. J Immunother Cancer. 2021 05; 9(5).
    View in: PubMed
    Score: 0.035
  28. Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes. Hum Gene Ther. 2001 Apr 10; 12(6):659-70.
    View in: PubMed
    Score: 0.035
  29. Inhibition of glioma cells in vitro and in vivo using a recombinant adenoviral vector containing an astrocyte-specific promoter. Cancer Gene Ther. 2000 Aug; 7(8):1120-6.
    View in: PubMed
    Score: 0.033
  30. T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T Cells. Clin Cancer Res. 2019 12 15; 25(24):7340-7350.
    View in: PubMed
    Score: 0.031
  31. "The end of the beginning": molecular and cellular biology of gene therapy keystone. 14-20 January 1999. Biochim Biophys Acta. 1999 Jul 29; 1424(1):R5-9.
    View in: PubMed
    Score: 0.031
  32. Use of gene marking technologies in oncology. Forum (Genova). 1998 Oct-Dec; 8(4):342-53.
    View in: PubMed
    Score: 0.029
  33. Gene and cell transfer for specific immunotherapy. Vox Sang. 1998; 74 Suppl 2:87-90.
    View in: PubMed
    Score: 0.028
  34. EBV specific CTL: a model for immune therapy. Vox Sang. 1998; 74 Suppl 2:497-8.
    View in: PubMed
    Score: 0.028
  35. Antitumor responses induced by transgenic expression of CD40 ligand. Hum Gene Ther. 1997 Nov 01; 8(16):1935-43.
    View in: PubMed
    Score: 0.028
  36. Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent. Cell Rep. 2017 Oct 03; 21(1):17-26.
    View in: PubMed
    Score: 0.027
  37. Emerging applications of gene transfer in the hematopoietic cancers. J Pediatr Hematol Oncol. 1997 Jan-Feb; 19(1):1-6.
    View in: PubMed
    Score: 0.026
  38. Gene transfer in haematological malignancy. Ann Med. 1996 Dec; 28(6):491-7.
    View in: PubMed
    Score: 0.026
  39. Gene marking. Hum Gene Ther. 1996 Oct 20; 7(16):1927-36.
    View in: PubMed
    Score: 0.026
  40. Gene transfer and therapeutic drug monitoring. Ther Drug Monit. 1996 Aug; 18(4):322-7.
    View in: PubMed
    Score: 0.025
  41. High-efficiency transduction of freshly isolated human tumor cells using adenoviral interleukin-2 vectors. Hum Gene Ther. 1996 Jun 20; 7(10):1233-9.
    View in: PubMed
    Score: 0.025
  42. Use of double marking with retroviral vectors to determine rate of reconstitution of untreated and cytokine expanded CD34+ selected marrow cells in patients undergoing autologous bone marrow transplantation. Hum Gene Ther. 1996 Mar 20; 7(5):655-67.
    View in: PubMed
    Score: 0.025
  43. Vectors in cancer therapy: how will they deliver? Cancer Gene Ther. 1995 Dec; 2(4):291-7.
    View in: PubMed
    Score: 0.024
  44. Human somatic gene therapy: progress and problems. J Intern Med. 1995 Mar; 237(3):229-39.
    View in: PubMed
    Score: 0.023
  45. Bortezomib sensitizes non-small cell lung cancer to mesenchymal stromal cell-delivered inducible caspase-9-mediated cytotoxicity. Cancer Gene Ther. 2014 Nov; 21(11):472-482.
    View in: PubMed
    Score: 0.022
  46. Current status of gene transfer into haemopoietic progenitor cells: application to Langerhans cell histiocytosis. Br J Cancer Suppl. 1994 Sep; 23:S56-7.
    View in: PubMed
    Score: 0.022
  47. Assessment of the efficacy of purging by using gene marked autologous marrow transplantation for children with AML in first complete remission. Hum Gene Ther. 1994 Apr; 5(4):481-99.
    View in: PubMed
    Score: 0.022
  48. Gene marking to improve the outcome of autologous bone marrow transplantation. J Hematother. 1994; 3(1):33-6.
    View in: PubMed
    Score: 0.021
  49. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol. 2014 Mar 10; 32(8):798-808.
    View in: PubMed
    Score: 0.021
  50. The immunogenicity of virus-derived 2A sequences in immunocompetent individuals. Gene Ther. 2013 Sep; 20(9):958-62.
    View in: PubMed
    Score: 0.020
  51. Gene transfer into human hematopoietic progenitor cells: a review of current clinical protocols. J Hematother. 1993; 2(1):7-17.
    View in: PubMed
    Score: 0.020
  52. Molecular analysis of retroviral transduction in chronic myelogenous leukemia. Hum Gene Ther. 1991; 2(4):317-21.
    View in: PubMed
    Score: 0.017
  53. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia. 2010 Jun; 24(6):1160-70.
    View in: PubMed
    Score: 0.016
  54. Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-gamma. J Immunother. 2009 Jun; 32(5):524-38.
    View in: PubMed
    Score: 0.015
  55. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 2009 Jun 18; 113(25):6392-402.
    View in: PubMed
    Score: 0.015
  56. Engineering human tumor-specific cytotoxic T cells to function in a hypoxic environment. Mol Ther. 2008 Mar; 16(3):599-606.
    View in: PubMed
    Score: 0.014
  57. Flanking-sequence exponential anchored-polymerase chain reaction amplification: a sensitive and highly specific method for detecting retroviral integrant-host-junction sequences. Cytotherapy. 2008; 10(5):526-39.
    View in: PubMed
    Score: 0.014
  58. Progress and prospects: gene therapy clinical trials (part 2). Gene Ther. 2007 Nov; 14(22):1555-63.
    View in: PubMed
    Score: 0.014
  59. Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood. 2007 Oct 15; 110(8):2793-802.
    View in: PubMed
    Score: 0.014
  60. IL-12 gene-modified bone marrow cell therapy suppresses the development of experimental metastatic prostate cancer. Cancer Gene Ther. 2007 Oct; 14(10):819-27.
    View in: PubMed
    Score: 0.014
  61. E1A-induced apoptosis does not prevent replication of adenoviruses with deletion of E1b in majority of infected cancer cells. Cancer Gene Ther. 2004 Sep; 11(9):585-93.
    View in: PubMed
    Score: 0.011
  62. Liposomal enhancement of the antitumor activity of conditionally replication-competent adenoviral plasmids. Mol Ther. 2004 Apr; 9(4):489-95.
    View in: PubMed
    Score: 0.011
  63. A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells. Cancer Gene Ther. 2004 Feb; 11(2):81-91.
    View in: PubMed
    Score: 0.011
  64. Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications. Blood. 2004 Feb 01; 103(3):1011-9.
    View in: PubMed
    Score: 0.010
  65. Selection of chronic lymphocytic leukemia binding peptides. Cancer Res. 2003 Sep 01; 63(17):5213-7.
    View in: PubMed
    Score: 0.010
  66. Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect. Mol Ther. 2003 Jun; 7(6):748-54.
    View in: PubMed
    Score: 0.010
  67. Bystander transfer of functional human CD40 ligand from gene-modified fibroblasts to B-chronic lymphocytic leukemia cells. Hum Gene Ther. 2003 Apr 10; 14(6):545-59.
    View in: PubMed
    Score: 0.010
  68. Expansion of EBV latent membrane protein 2a specific cytotoxic T cells for the adoptive immunotherapy of EBV latency type 2 malignancies: influence of recombinant IL12 and IL15. Cytotherapy. 2003; 5(3):231-40.
    View in: PubMed
    Score: 0.010
  69. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus--positive Hodgkin's lymphoma. Int J Cancer. 2001 Sep 01; 93(5):706-13.
    View in: PubMed
    Score: 0.009
  70. Transduction of human PBMC-derived dendritic cells and macrophages by an HIV-1-based lentiviral vector system. Mol Ther. 2000 Feb; 1(2):171-9.
    View in: PubMed
    Score: 0.008
  71. Gene-marked autologous hematopoietic stem cell transplantation of autoimmune disease. J Clin Immunol. 2000 Jan; 20(1):1-9.
    View in: PubMed
    Score: 0.008
  72. Transduction of CD34(+) and CD34(-)/lin(-) hemopoietic progenitors by lentivirus vectors. Cytotherapy. 1999; 1(6):433-8.
    View in: PubMed
    Score: 0.007
  73. Increased transduction efficiency of primary hematopoietic cells by physical colocalization of retrovirus and target cells. J Hematother. 1998 Jun; 7(3):217-24.
    View in: PubMed
    Score: 0.007
  74. Administration of neomycin resistance gene marked EBV specific cytotoxic T-lymphocytes to patients with relapsed EBV-positive Hodgkin disease. Hum Gene Ther. 1998 May 20; 9(8):1237-50.
    View in: PubMed
    Score: 0.007
  75. Expression of the human immunodeficiency virus type 1 primer binding sequence inhibits HIV-1 replication. Hum Gene Ther. 1998 Mar 01; 9(4):587-90.
    View in: PubMed
    Score: 0.007
  76. Stereotactic injection of herpes simplex thymidine kinase vector producer cells (PA317-G1Tk1SvNa.7) and intravenous ganciclovir for the treatment of progressive or recurrent primary supratentorial pediatric malignant brain tumors. Hum Gene Ther. 1995 Sep; 6(9):1231-55.
    View in: PubMed
    Score: 0.006
  77. Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts. Hum Gene Ther. 1994 Mar; 5(3):381-97.
    View in: PubMed
    Score: 0.005
  78. Use of cell-free retroviral vector preparations for transduction of cells from the marrow of chronic phase and blast crisis chronic myelogenous leukemia patients and from normal individuals. Hum Gene Ther. 1992 Apr; 3(2):137-45.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.